Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) closed at $15.64 in the last session, down -10.58% from day before closing price of $17.49. In other words, the price has decreased by -$10.58 from its previous closing price. On the day, 0.9 million shares were traded. TNXP stock price reached its highest trading level at $17.49 during the session, while it also had its lowest trading level at $14.7001.
Ratios:
We take a closer look at TNXP’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.04 and its Current Ratio is at 6.50. In the meantime, Its Debt-to-Equity ratio is 0.06 whereas as Long-Term Debt/Eq ratio is at 0.04.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TNXP now has a Market Capitalization of 107569104 and an Enterprise Value of 9984539. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.66 while its Price-to-Book (P/B) ratio in mrq is 0.49. Its current Enterprise Value per Revenue stands at 0.989 whereas that against EBITDA is -0.134.
Stock Price History:
The Beta on a monthly basis for TNXP is 1.61, which has changed by -0.9742763 over the last 52 weeks, in comparison to a change of -0.024663687 over the same period for the S&P500. Over the past 52 weeks, TNXP has reached a high of $672.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -13.22%, while the 200-Day Moving Average is calculated to be -48.49%.
Shares Statistics:
According to the various share statistics, TNXP traded on average about 1.68M shares per day over the past 3-months and 1900770 shares per day over the past 10 days. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.32% stake in the company. Shares short for TNXP as of 1741910400 were 878522 with a Short Ratio of 0.52, compared to 1739491200 on 333835. Therefore, it implies a Short% of Shares Outstanding of 878522 and a Short% of Float of 13.65.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Tonix Pharmaceuticals Holding Corp (TNXP) is a result of the insights provided by 1.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$2.68, with high estimates of -$2.68 and low estimates of -$2.68.
Analysts are recommending an EPS of between -$11.89 and -$11.89 for the fiscal current year, implying an average EPS of -$11.89. EPS for the following year is -$4.67, with 1.0 analysts recommending between -$4.67 and -$4.67.
Revenue Estimates
According to 2 analysts, the current quarter’s revenue is expected to be $2.55M. It ranges from a high estimate of $2.6M to a low estimate of $2.5M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $2.48MFor the next quarter, 2 analysts are estimating revenue of $2.65M. There is a high estimate of $2.8M for the next quarter, whereas the lowest estimate is $2.5M.
A total of 2 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $11.1M, while the lowest revenue estimate was $11.1M, resulting in an average revenue estimate of $11.1M. In the same quarter a year ago, actual revenue was $10.09MBased on 2 analysts’ estimates, the company’s revenue will be $98.7M in the next fiscal year. The high estimate is $166.1M and the low estimate is $31.3M.
